Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P48167
UPID:
GLRB_HUMAN
Alternative names:
Glycine receptor 58 kDa subunit
Alternative UPACC:
P48167; A8K3K2; D3DP23; F5GWE1
Background:
The Glycine receptor subunit beta, a 58 kDa protein, is integral to the formation of heteromeric ligand-gated chloride channels, activated by glycine. It plays a pivotal role in reducing neuronal excitability and is essential for generating inhibitory postsynaptic currents.
Therapeutic significance:
Linked to Hyperekplexia 2, a neurological disorder marked by muscular rigidity and an exaggerated startle response, understanding the Glycine receptor subunit beta's function could unveil new therapeutic avenues.